Efficacy and Tolerability of Entospletinib in Combination With Systemic Corticosteroids as First-Line Therapy in Adults With Chronic Graft Versus Host Disease (cGVHD)

PHASE2TerminatedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

May 27, 2016

Primary Completion Date

December 19, 2017

Study Completion Date

March 6, 2018

Conditions
Chronic Graft Versus Host Disease
Interventions
DRUG

ENTO

Tablets administered orally

DRUG

Placebo

Tablets administered orally

Trial Locations (30)

39008

Hospital Universitario Marques de Valdecilla, Santander

46009

Hospital Universitario La Fe, Valencia

60590

Universitatsklinikum Frankfurt, Frankfurt am Main

Unknown

University of Miami, Miami

Emory University, Atlanta

Loyola University Medical Center, Maywood

University of Kansas Cancer Center, Westwood

Weill Cornell Medical Center, New York

Duke University Medical Center, Durham

Taussig Cancer Institute, Cleveland

Ohio State University, Wexner Medical Center, Columbus

Vanderbilt University, Nashville

Princess Margaret, Toronto

Institut Paoli Calmettes, Marseille

Hopital Saint Louis, Paris

Institut Gustave Roussy, Villejuif

Universitätsklinikum Carl Gustav Carus, Dresden

Universitatsklinikum Hamburg-Eppendorf, Hamburg

Klinikum der Universitaet Regensburg, Regensburg

Pusan National University Hospital, Busan

Samsung Medical Center, Seoul

Severance Hospital, Yonsei University Health System, Seoul

Hospital Universitario Vall d'Hebron, Barcelona

Hospital General Universitario Gregorio Marañon, Madrid

Hospital Universitario de Salamanca, Salamanca

Hospital Universitario Virgen del Rocio, Seville

Hospital Clinico Universitario de Valencia, Valencia

Kings College Hospital NHS Trust, London

St Bartholomew's Hospital, London

Manchester Royal Infirmary, Manchester

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Gilead Sciences

INDUSTRY

NCT02701634 - Efficacy and Tolerability of Entospletinib in Combination With Systemic Corticosteroids as First-Line Therapy in Adults With Chronic Graft Versus Host Disease (cGVHD) | Biotech Hunter | Biotech Hunter